JP2023025151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023025151A5 JP2023025151A5 JP2022192575A JP2022192575A JP2023025151A5 JP 2023025151 A5 JP2023025151 A5 JP 2023025151A5 JP 2022192575 A JP2022192575 A JP 2022192575A JP 2022192575 A JP2022192575 A JP 2022192575A JP 2023025151 A5 JP2023025151 A5 JP 2023025151A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- cell
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 39
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001413 amino acids Chemical group 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000003446 ligand Substances 0.000 claims 8
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 4
- 102000000853 LDL receptors Human genes 0.000 claims 4
- 108010001831 LDL receptors Proteins 0.000 claims 4
- 102000007238 Transferrin Receptors Human genes 0.000 claims 4
- 108010033576 Transferrin Receptors Proteins 0.000 claims 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 4
- 150000002224 folic acids Chemical class 0.000 claims 4
- -1 small molecule compounds Chemical class 0.000 claims 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- VVEJUSYNERNRME-XGFVQVCISA-N (4r,7s,10r,13s,16r,19s,22r,25s,28r,31s)-13,28-bis(4-aminobutyl)-25-(2-amino-2-oxoethyl)-31-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-19,22-dibenzyl-10-[(1r)-1-hydroxyethyl]-7-(hydroxymethyl)-16-(1h-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo- Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 VVEJUSYNERNRME-XGFVQVCISA-N 0.000 claims 2
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims 2
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108700012941 GNRH1 Proteins 0.000 claims 2
- 101500024338 Homo sapiens Somatostatin-14 Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 102000023108 LH Receptors Human genes 0.000 claims 2
- 108010011942 LH Receptors Proteins 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 102400000820 Somatostatin-14 Human genes 0.000 claims 2
- 102000003569 TRPV6 Human genes 0.000 claims 2
- 101150096736 TRPV6 gene Proteins 0.000 claims 2
- 102100029569 Transient receptor potential cation channel subfamily V member 6 Human genes 0.000 claims 2
- 108700039207 Transient receptor potential cation channel subfamily V member 6 Proteins 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims 2
- 235000007635 levomefolic acid Nutrition 0.000 claims 2
- 239000011578 levomefolic acid Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- FMJUDUJLTNVWCH-UHFFFAOYSA-N 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid Chemical group CCOC(C(O)=O)CC1=CC=C(O)C=C1 FMJUDUJLTNVWCH-UHFFFAOYSA-N 0.000 claims 1
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 claims 1
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 claims 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 claims 1
- 108010068380 arginylarginine Proteins 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- VLXBWPOEOIIREY-UHFFFAOYSA-N dimethyl diselenide Natural products C[Se][Se]C VLXBWPOEOIIREY-UHFFFAOYSA-N 0.000 claims 1
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical group CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 150000003883 epothilone derivatives Chemical class 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000015210 hypertensive heart disease Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 claims 1
- 108010004914 prolylarginine Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510489556.6A CN106466485B (zh) | 2015-08-11 | 2015-08-11 | 一种具有细胞内吞介导功能的靶向配体-药物偶联体 |
| CN201510489560.2 | 2015-08-11 | ||
| CN201510489560.2A CN106466484B (zh) | 2015-08-11 | 2015-08-11 | 一种具有细胞内吞介导功能的多靶向配体-药物偶联体 |
| CN201510489556.6 | 2015-08-11 | ||
| JP2020164335A JP7573401B2 (ja) | 2015-08-11 | 2020-09-30 | 多リガンド－薬物複合体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020164335A Division JP7573401B2 (ja) | 2015-08-11 | 2020-09-30 | 多リガンド－薬物複合体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023025151A JP2023025151A (ja) | 2023-02-21 |
| JP2023025151A5 true JP2023025151A5 (enExample) | 2023-03-29 |
Family
ID=57983917
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568345A Active JP6772199B2 (ja) | 2015-08-11 | 2016-08-11 | 多リガンド−薬物複合体及びその使用 |
| JP2020164335A Active JP7573401B2 (ja) | 2015-08-11 | 2020-09-30 | 多リガンド－薬物複合体及びその使用 |
| JP2022192575A Pending JP2023025151A (ja) | 2015-08-11 | 2022-12-01 | 多リガンド－薬物複合体及びその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568345A Active JP6772199B2 (ja) | 2015-08-11 | 2016-08-11 | 多リガンド−薬物複合体及びその使用 |
| JP2020164335A Active JP7573401B2 (ja) | 2015-08-11 | 2020-09-30 | 多リガンド－薬物複合体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11571480B2 (enExample) |
| EP (1) | EP3334500B1 (enExample) |
| JP (3) | JP6772199B2 (enExample) |
| KR (2) | KR102301596B1 (enExample) |
| CN (3) | CN111617250B (enExample) |
| AU (2) | AU2016305703B2 (enExample) |
| CA (1) | CA2987322C (enExample) |
| DK (1) | DK3334500T3 (enExample) |
| ES (1) | ES2877409T3 (enExample) |
| MX (1) | MX381031B (enExample) |
| RU (1) | RU2722449C2 (enExample) |
| WO (1) | WO2017025057A1 (enExample) |
| ZA (1) | ZA201707464B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5836940B2 (ja) | 2009-06-26 | 2015-12-24 | ソリシメド・バイオファーマ・インコーポレーテッド | ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法 |
| CA2987322C (en) * | 2015-08-11 | 2020-02-11 | Coherent Biopharma | Multi-ligand drug conjugates and uses thereof |
| EP3716991A4 (en) * | 2017-12-01 | 2021-09-08 | Soricimed Biopharma Inc. | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| EP3720842A4 (en) | 2017-12-06 | 2021-11-03 | Ontario Institute For Cancer Research | ACYLHYDRAZONE LINKERS, METHODS, AND USES THEREOF |
| WO2019119141A1 (en) | 2017-12-22 | 2019-06-27 | Ontario Institute For Cancer Research (Oicr) | Heterocyclic acyl hydrazone linkers, methods and uses thereof |
| WO2019134018A1 (en) * | 2018-01-05 | 2019-07-11 | Telethon Kids Institute | Vaccine conjugates and uses thereof |
| JP7546574B2 (ja) * | 2019-01-30 | 2024-09-06 | コヒレント バイオファーマ （スーチョウ），リミテッド | 二重リガンド薬物コンジュゲート及びその使用 |
| CA3147895A1 (en) * | 2019-07-22 | 2021-01-28 | Purdue Research Foundation | Multivalent fibroblast-targeted agents and methods of use |
| EP4047098A4 (en) * | 2019-08-20 | 2023-06-07 | EGI Tech (Shen Zhen) Co., Limited | PROCEDURE FOR SEQUENCING POLYNUCLEOTIDS BASED ON OPTICAL SIGNAL DYNAMICS OF A LUMINESCENT LABEL AND SECONDARY LUMINESCENT SIGNAL |
| WO2021163701A1 (en) * | 2020-02-13 | 2021-08-19 | Escape Therapeutics, Inc. | Melanoma therapeutics |
| EP4274595A4 (en) * | 2021-01-07 | 2026-01-21 | Purdue Research Foundation | FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS AND ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM |
| TW202317199A (zh) * | 2021-06-25 | 2023-05-01 | 大陸商同宜醫藥（蘇州）有限公司 | 配體藥物偶聯物及其應用 |
| CN116059392B (zh) * | 2021-09-03 | 2025-02-28 | 同宜医药（苏州）有限公司 | 配体偶联物及其应用 |
| AU2022344391B2 (en) * | 2021-09-08 | 2026-02-05 | Coherent Biopharma (Suzhou) Limited | Pharmaceutical preparation, preparation method therefor and use thereof |
| WO2023066251A1 (zh) * | 2021-10-19 | 2023-04-27 | 同宜医药（苏州）有限公司 | 偶联体药物制剂及其制备方法和用途 |
| CN116196408B (zh) * | 2021-12-30 | 2026-01-06 | 思格(苏州)生物科技有限公司 | 一种新型免疫佐剂及其制备方法和应用 |
| TW202404643A (zh) * | 2022-04-20 | 2024-02-01 | 大陸商同宜醫藥（蘇州）有限公司 | 化合物及用途 |
| WO2024099387A1 (zh) * | 2022-11-09 | 2024-05-16 | 同宜医药（苏州）有限公司 | 通过施用配体-药物偶联体治疗癌症 |
| CN120813385A (zh) * | 2023-03-23 | 2025-10-17 | 同宜医药（苏州）有限公司 | 通过施用配体-药物偶联体治疗卵巢癌 |
| CN121001746A (zh) * | 2023-04-26 | 2025-11-21 | 同宜医药（苏州）有限公司 | 一种配体-药物偶联体在治疗癌症中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| AU2002337954C1 (en) * | 2001-10-22 | 2008-10-23 | The Scripps Research Institute | Integrin targeting compounds |
| WO2003072754A2 (en) * | 2002-02-27 | 2003-09-04 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| GB0209893D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US7119168B2 (en) * | 2002-11-18 | 2006-10-10 | Bioprospecting Nb Inc. | Paralytic peptide for use in neuromuscular therapy |
| JP5008981B2 (ja) | 2003-12-05 | 2012-08-22 | アロジーン， インコーポレイテッド | ポリリンゴ酸ベースの多機能性薬物送達システム |
| US20100166654A1 (en) | 2004-12-03 | 2010-07-01 | The Uab Research Foundation | Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery |
| RU2470668C2 (ru) | 2005-08-19 | 2012-12-27 | Эндосайт, Инк. | Конъюгаты лиганда с несколькими лекарственными средствами |
| EA016577B1 (ru) | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
| MX2009002855A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| US20080181852A1 (en) | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
| CN101224306B (zh) | 2008-02-20 | 2011-04-20 | 中山大学 | 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法 |
| CN102231951A (zh) * | 2008-11-17 | 2011-11-02 | 安龙制药公司 | 用于核酸传递系统的可释放的偶联物 |
| CN102282168A (zh) * | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2012019121A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Trustees Of The University Of Illinois | Multiplexed supramolecular assemblies for non-viral delivery of genetic material |
| HUE052285T2 (hu) | 2011-06-06 | 2021-04-28 | Starpharma Pty Ltd | Makromolekulák |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| CN103372199B (zh) * | 2012-04-16 | 2015-12-16 | 广州暨南大学医药生物技术研究开发中心 | 一种预防和治疗神经退行性疾病的新型脑部靶向制剂 |
| US9545449B2 (en) * | 2012-05-11 | 2017-01-17 | Advanced Proteone Therapeutics Inc. | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| GB201211309D0 (en) | 2012-06-26 | 2012-08-08 | Fujifilm Mfg Europe Bv | Process for preparing membranes |
| AU2013288932A1 (en) | 2012-07-09 | 2014-12-11 | Genentech, Inc. | Immunoconjugates comprising anti - CD79b antibodies |
| PL2872157T3 (pl) * | 2012-07-12 | 2020-07-13 | Hangzhou Dac Biotech Co., Ltd | Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| US10253099B2 (en) | 2012-12-05 | 2019-04-09 | Ruprecht-Karls-Universität Heidelberg | Conjugates of proteins and multivalent cell-penetrating peptides and their uses |
| MX2015013163A (es) * | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| AU2014337317A1 (en) | 2013-10-15 | 2016-09-15 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| CN104784699B (zh) * | 2014-01-20 | 2019-05-03 | 博瑞生物医药（苏州）股份有限公司 | 叶酸受体结合配体-药物偶联物 |
| EP3164420A4 (en) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| CN104667292B (zh) * | 2015-02-02 | 2017-09-05 | 北京大学 | 一种还原响应型药物偶联物纳米粒的制备及其应用 |
| JP6987641B2 (ja) * | 2015-05-12 | 2022-01-05 | ブリンクバイオ インコーポレイテッド | シリコン系薬物複合体及びその使用方法 |
| CA2987322C (en) * | 2015-08-11 | 2020-02-11 | Coherent Biopharma | Multi-ligand drug conjugates and uses thereof |
| JP2020164335A (ja) * | 2019-03-28 | 2020-10-08 | イビデン株式会社 | ハニカム構造体 |
-
2016
- 2016-08-11 CA CA2987322A patent/CA2987322C/en active Active
- 2016-08-11 KR KR1020187003716A patent/KR102301596B1/ko active Active
- 2016-08-11 JP JP2017568345A patent/JP6772199B2/ja active Active
- 2016-08-11 RU RU2018104266A patent/RU2722449C2/ru active
- 2016-08-11 KR KR1020207016784A patent/KR102464778B1/ko active Active
- 2016-08-11 DK DK16834681.5T patent/DK3334500T3/da active
- 2016-08-11 MX MX2018001723A patent/MX381031B/es unknown
- 2016-08-11 ES ES16834681T patent/ES2877409T3/es active Active
- 2016-08-11 CN CN202010115950.4A patent/CN111617250B/zh active Active
- 2016-08-11 AU AU2016305703A patent/AU2016305703B2/en active Active
- 2016-08-11 CN CN201680045855.3A patent/CN108135881B/zh active Active
- 2016-08-11 US US15/751,541 patent/US11571480B2/en active Active
- 2016-08-11 CN CN202011155574.8A patent/CN112263683A/zh active Pending
- 2016-08-11 EP EP16834681.5A patent/EP3334500B1/en active Active
- 2016-08-11 WO PCT/CN2016/094704 patent/WO2017025057A1/en not_active Ceased
-
2017
- 2017-11-03 ZA ZA2017/07464A patent/ZA201707464B/en unknown
-
2019
- 2019-10-02 AU AU2019240611A patent/AU2019240611B2/en active Active
-
2020
- 2020-09-30 JP JP2020164335A patent/JP7573401B2/ja active Active
-
2022
- 2022-10-06 US US17/961,397 patent/US20240100175A1/en active Pending
- 2022-12-01 JP JP2022192575A patent/JP2023025151A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021006549A5 (enExample) | ||
| RU2018104266A (ru) | Полилигандные лекарственные конъюгаты и их применения | |
| AU2020214507B2 (en) | Bi-ligand drug conjugate and use thereof | |
| US20200392108A1 (en) | Antibody-drug conjugates and related compounds, compositions and methods | |
| ES2908470T3 (es) | Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos | |
| WO2020177627A1 (zh) | 一种双特异抗体 | |
| JP2015526435A (ja) | 抗体成分と血液脳関門を通過するポリペプチドと細胞毒とを含むコンジュゲート | |
| KR20160064726A (ko) | 세포 투과 펩타이드-항암제 접합체 및 이를 포함하는 암 치료용 조성물 | |
| US20250262307A1 (en) | Conjugates of psma-binding moieties with cytotoxic agents | |
| EP4682156A1 (en) | Linker and drug conjugate using same, and antibody-drug conjugate and use thereof | |
| US20230173083A1 (en) | Albumin-binding prodrug for preventing or treating cancer and pharmaceutical composition including the same | |
| US20190321484A1 (en) | Antibody drug conjugates | |
| KR101095396B1 (ko) | 암 표적지향형 트랜스페린-폴리에틸렌 글리콜이 수식된 트레일, 이의 제조 및 용도 | |
| HK40130456A (en) | Bi-ligand drug conjugate and use thereof | |
| WO2025206033A1 (ja) | ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物 | |
| HK40052006A (en) | Bi-ligand drug conjugate and use thereof | |
| JP2022530823A (ja) | がん治療のためのペプチド誘導体とそのコンジュゲート | |
| HK40061762A (en) | Bi-ligand drug conjugate and use thereof | |
| BR112018009225B1 (pt) | Conjugado de anticorpo anti-cd22, seu uso e composição farmacêutica compreendendo o mesmo | |
| HK1253921B (en) | Multi-ligand drug conjugates and uses thereof |